Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Investment Securities (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Gains from Investment Securities data on record, last reported at $5990.0 in Q1 2025.

  • For Q1 2025, Gains from Investment Securities fell 90.78% year-over-year to $5990.0; the TTM value through Mar 2025 reached $5990.0, down 90.78%, while the annual FY2024 figure was $335448.0, 15.13% up from the prior year.
  • Gains from Investment Securities reached $5990.0 in Q1 2025 per CYCN's latest filing, down from $65000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $450000.0 in Q2 2021 and bottomed at -$92000.0 in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $37941.5, with a median of -$91000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: plummeted 171.09% in 2021, then surged 171.43% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$92000.0 in 2021, then changed by 0.0% to -$92000.0 in 2022, then skyrocketed by 112.23% to $11250.0 in 2023, then surged by 477.78% to $65000.0 in 2024, then tumbled by 90.78% to $5990.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $5990.0 in Q1 2025, $65000.0 in Q1 2024, and $11250.0 in Q3 2023.